It has been found to reduce fatty liver disease and steatohepatitis, a disorder of lipid metabolism in non-alcoholic fatty liver disease mice, through upward regulation of the FGF21/FGFR1 pathway [28]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.